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Abstract
Background: Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been
associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy
(ART) with concurrent active TB or other AIDS-defining disease using data from the ‘‘Prospective Evaluation of Antiretrovirals
in Resource-Limited Settings’’ (PEARLS) study.
Methods: Participants were categorized retrospectively into three groups according to presence of active confirmed or
presumptive disease at ART initiation: those with pulmonary and/or extrapulmonary TB (‘‘TB’’ group), those with other non-
TB AIDS-defining disease (‘‘other disease’’), or those without concurrent TB or other AIDS-defining disease (‘‘no disease’’).
Primary outcome was time to the first of virologic failure, HIV disease progression or death. Since the groups differed in
characteristics, proportional hazard models were used to compare the hazard of the primary outcome among study groups,
adjusting for age, sex, country, screening CD4 count, baseline viral load and ART regimen.
Results: 31 of 102 participants (30%) in the ‘‘TB’’ group, 11 of 56 (20%) in the ‘‘other disease’’ group, and 287 of 1413 (20%)
in the ‘‘no disease’’ group experienced a primary outcome event (p=0.042). This difference reflected higher mortality in the
TB group: 15 (15%), 0 (0%) and 41 (3%) participants died, respectively (p,0.001). The adjusted hazard ratio comparing the
‘‘TB’’ and ‘‘no disease’’ groups was 1.39 (95% confidence interval: 0.93–2.10; p=0.11) for the primary outcome and 3.41
(1.72–6.75; p,0.001) for death.
Conclusions: Active TB at ART initiation was associated with increased risk of mortality in HIV-1 infected patients.
Citation: Pe ´risse ´ ARS, Smeaton L, Chen Y, La Rosa A, Walawander A, et al. (2013) Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy
with Concurrent Active TB or Other AIDS-Defining Disease. PLoS ONE 8(12): e83643. doi:10.1371/journal.pone.0083643
Editor: Petros C. Karakousis, Johns Hopkins University School of Medicine, United States of America
Received August 9, 2013; Accepted November 5, 2013; Published December 31, 2013
Copyright:  2013 Pe ´risse ´ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project described was supported by Award Numbers UMAI068634 and UMAI068636 from the National Institute of Allergy and Infectious Diseases
and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the
responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National
Institutes of Health. Bristol Myers Squibb provided atazanavir, didanosine-EC and efavirenz (with consent of Merck); Gilead Sciences, Inc. provided emtricitabine,
tenofovir-DF, emtricitabine/tenofovir-DF and financial support for purchase of other study drugs; GlaxoSmithKline provided lamivudine, zidovudine and
lamivudine/zidovudine; and Boehringer Ingelheim Pharmaceuticals, Inc. provided nevirapine. This does not alter the authors’ adherence to all the PLOS ONE
policies on sharing data and materials. Employees of the NIAID participated as study team members and authors of this manuscript. The NIAID provided
recommendations on the study design and approved the final study design, but had no role in data collection and analysis, decision to publish, or preparation of
the manuscript. Bristol Myers Squibb, Gilead Sciences Inc., GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals, Inc. had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript. Representatives of the pharmaceutical company sponsors participated as study
team members and authors of this manuscript, but did not participate in data collection, data analyses or interpretation.
Competing Interests: Thomas Campbell declares previously receiving payment for being an advisory board member for Gliead Sciences. Laura Smeaton
declare being a paid data monitoring member for Pfizer. Michael Hughes declares previously being a paid data monitoring committee member for Boehringer
Ingelheim, Medicines Development, Pfizer and Tibotec. All other authors have no potential conflicts of interest to declare. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: aperisse@ensp.fiocruz.br
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83643Introduction
The benefits of highly active antiretroviral therapy (ART) are
unequivocal and their widespread use in developed countries has
reduced HIV-associated morbidity and mortality [1–3]. Approx-
imately 30–60% of all newly diagnosed HIV-infected persons
present to clinics with either an AIDS-defining disease or a CD4+
cell count lower than 350 cells/mm
3 [4,5]. Despite effective viral
suppression and reduced HIV-associated morbidity and mortality
among these persons, there may be less than ideal immune
reconstitution of CD4 cells, higher incidence of immune recon-
stitution inflammatory syndrome (IRIS), and interactions between
antiretroviral therapy (ART) regimens and drugs used to treat
opportunistic infections (OI) [6–8]. Mortality rates subsequent to
an episode of AIDS-defining disease may depend on the specific
disease [9].
Tuberculosis (TB) is the most common AIDS-defining disease in
several resource-limited countries (RLC) [10,11]. A recent meta-
analysis of cohort studies has shown that TB was associated with
poor survival among HIV-infected individuals not receiving ART
but not among those receiving ART [11]. However, response to
ART may be related to timing of ART initiation during TB
treatment [12–14] and CD4+ cell count at treatment initiation
[15]. The World Health Organization (WHO) recommends start
of ART as soon as possible in all HIV/TB co-infected patients
with active TB and within the first eight weeks of starting TB
treatment [16]. The Centers for Disease Control and Prevention
(CDC) recommendation varies from 2 to 4 weeks depending on
CD4 count and clinical setting [17]. Current evidence indicates a
benefit for starting ART within the first 2 weeks of treatment for
Pneumocystis jirovecii pneumonia (PCP) and serious bacterial
infections [18]. Less information is available for other non-TB
AIDS-defining diseases and no formal recommendation is made,
except for ART initiation as soon as the clinical condition allows,
mainly for diseases in which a specific treatment is not available
and ART is the current recommended treatment [16,18,19].
The aim of this report is to investigate the impact of ART on
morbidity (time to AIDS-defining diseases and virologic failure)
and mortality (all-cause death) for ART-naı ¨ve HIV-1-infected
patients presenting with a diagnosis of TB or other AIDS-defining
disease at study entry compared to those presenting without any
ongoing (active) AIDS-defining disease in the setting of an
international multicenter ART trial in RLC [20].
Materials and Methods
The AIDS Clinical Trials Group (ACTG) Prospective Evalu-
ation of Antiretrovirals in Resource- Limited Settings (PEARLS,
also known as ACTG A5175; ClinicalTrials.gov NCT00084136)
study was a phase IV, prospective, randomized, open-label
evaluation of the efficacy of once-daily protease inhibitor and
once-daily non-nucleoside reverse transcriptase inhibitor antiret-
roviral combinations for the initial treatment of HIV-1-infected
individuals from nine countries in Africa, Asia, the Caribbean, and
North and South America. The participants were $18 years old,
had documented HIV-1 infection, had received no more than 7
days of cumulative prior ART (prior use of single-dose nevirapine
or zidovudine for any duration to prevent mother-to-child
transmission of HIV was allowed), and had a CD4 cell count
,300 cells/mm
3 within 90 days prior to entry into the study. All
participants had baseline clinical assessments for co-morbid
conditions and those with an AIDS-defining disease were allowed
to enroll only if stable and having already completed at least 14
days of treatment for that condition, if applicable. Participants
were randomized to one of the following arms: A, lamivudine/
zidovudine+efavirenz (3TC/ZDV+EFV); B, didanosine_EC+em-
tricitabine+atazanavir (DDI-EC+FTC+ATV); C, emtricitabine/
tenofovir-DF+efavirenz (FTC/TDF+EFV). Visits were scheduled
at screening, entry, and weeks 2, 4, 8, 12, 16, 20, 24, and every 8
weeks thereafter; follow-up continued for the duration of the study
irrespective of changes in antiretroviral therapy. Enrollment
occurred between May 2005 and July 2007, and participants
were followed through to April/May 2010. Further details about
this study are reported elsewhere [20].
Diagnosis of TB and AIDS-defining diseases at all study
locations used standard ACTG definitions, including categoriza-
tion as either confirmed or presumptive [20]. A panel of five
physician team members, who were blinded to participant
identity, clinic site, demographic characteristics and study
treatment, then reviewed the supporting clinical and laboratory
data for each diagnosis and made a final classification of each
diagnosis according to these definitions. For analysis purposes,
participants were categorized retrospectively into one of three
study groups based on the presence or not of an active confirmed
or presumptive disease at the time of ART initiation: (1) those with
a concurrent diagnosis of pulmonary and/or extra pulmonary TB
– PTB/ETB (the ‘‘TB’’ group), (2) those with any other concurrent
AIDS-defining disease (the ‘‘other AIDS-defining disease’’ group),
or (3) those without TB or other AIDS-defining disease (the ‘‘no
disease’’ group).
The study’s primary outcome (and the outcome of interest in
this report), was the time from randomization to the first of any of
the following events: virologic failure – defined as plasma HIV-1
RNA $1000 copies/mL on two consecutive measurements
obtained at the week 16 visit or later; disease progression –
defined as a new or recurrent AIDS-defining OI or malignancy
occurring at least 12 weeks following randomization and not
associated with a diagnosis of IRIS (Immune Reconstitution
Inflammatory Syndrome); or death due to any cause. If a
participant failed to attend a scheduled follow-up visit, sites were
required to assess the reason for missed visit. If death was the
reason for a missed visit, sites were required to report the date of
death, the suspected cause of death, relationship to study
treatment and the sources of death-related information.
Differences in age, sex, country, screening CD4 count, baseline
viral load (VL, measured by plasma HIV-1 RNA level) and chance
imbalance by randomized ART regimen among the three baseline
disease status groups (‘‘TB’’, ‘‘other AIDS-defining disease’’ and
‘‘no disease’’) were evaluated using the chi-square test for
categorical variables and analysis of variance for continuous
variables. Comparison between groups in time from diagnosis of
concurrent disease to randomization used the Wilcoxon Rank-
Sum Test. The Kaplan-Meier method estimated, and the log-rank
test compared, the cumulative probability of the primary outcome
over time among the study groups. Participants lost to follow-up
were considered censored at the date of last contact. Cox
proportional hazard models compared the relative hazard of the
primary outcome, while adjusting for other baseline covariates
listed above. To evaluate whether any study group differences
varied by assigned ART regimen, a term for the interaction of
ART arm and study group was included in the model. Other first
order interaction terms were also tested. Similar methods were
used to analyze the time to each of the three, separate components
of the primary outcome, i.e., time to virologic failure, time to
disease progression, and time to death.
On May 6, 2008, the independent Data and Safety Monitoring
Board (DSMB) for the study recommended stopping treatment
with the once-daily protease inhibitor-based regimen (arm B) due
to conclusive evidence of inferiority compared to the control arm
ART Initiation and Opportunistic Infection
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boards, and ethics committees were then informed of the DSMB
findings and participants still taking ATV+DDI-EC+FTC were
switched to alternative antiretroviral regimens and continued
follow-up, but assigned study treatment in the other arms
continued. In our analysis we used data for the entire follow-up
available for each participant. A different approach, censoring the
follow-up of participants in arm B in May 2008, gave similar
results, and therefore, only results from the former analysis are
presented here.
Written informed consent was obtained from all participants,
and the human experimentation guidelines of the US Department
of Health and Human Services were followed. The study was
approved by the Colorado Multiple Institutional Review Board,
University of Colorado (USA) and local Ethics Committees at each
participating institution in Brazil, Haiti, India, Malawi, Peru,
South Africa, Thailand and Zimbabwe.
Results
Between May 2005 and July 2007, a total of 1,571 HIV-1
positive individuals were enrolled and randomly assigned to one of
the three ART arms. One hundred two participants (6.5% of the
study population) had concurrent tuberculosis at ART initiation,
83 PTB and 19 ETB. Fifty-six participants (3.6% of the study
population) had other AIDS-defining disease (18 mucocutaneous
herpes simplex, 10 wasting syndrome, 9 disseminated fungal
disease, 5 Kaposi sarcoma, 4 toxoplasmic encephalitis, 3
esophageal candidiasis, 2 cytomegalovirus retinitis, 2 PCP, 1
cryptococcal meningitis, 1 HIV-associated dementia and 1
Mycobacterium avium complex). Excluding recurrent and chronic
AIDS-defining diseases, the median time from the diagnosis of the
concurrent AIDS defining disease to ART initiation was 14 weeks
(range, 0–77) for participants in the ‘‘TB’’ group and 8 weeks
(range, 1–348) for those in the ‘‘other AIDS-defining disease’’
group (p=0.002). The remaining 1,413 participants (90% of the
study population) did not have a concurrent diagnosis and
therefore made up the ‘‘no disease’’ group. The median time of
follow-up from randomization to a primary outcome or censoring
was 178 weeks (range, 3–241) in the ‘‘TB group’’, 168 weeks
(range, 0–256) in the ‘‘other AIDS-defining disease’’ group, and
176 weeks (range, 0–261) in the ‘‘no disease’’ group. Only 63 of
the 1,571 participants (4%) received ART before entering the
study. Of those, 57 were in the ‘‘no disease’’ group and only 3 in
each of the ‘‘TB’’ and ‘‘other AIDS-defining disease’’ groups.
Except for age and randomized treatment, the selected baseline
characteristics of the participants differed significantly among
disease groups (Table 1). Participants in the ‘‘other AIDS-defining
disease’’ group were more likely to be male (79%) than those in the
‘‘TB’’ group (58%) and ‘‘no disease’’ group (52%). Diseases were
distributed unequally among countries: approximately 80% of all
TB cases were reported from participants from either India (56%)
or South Africa (27%), while approximately 60% of participants
with other AIDS-defining diseases were from Peru (27%) and the
United States (34%). Seventy-eight percent of participants in the
‘‘TB’’ group and 71% in the ‘‘other AIDS-defining disease’’ group
had CD4 count below 200 cells/mm
3, compared with 59% in the
‘‘no disease’’ group. In fact, 32% of participants in the ‘‘other
AIDS-defining disease’’ group had CD4 count below 50 cells/
mm
3 compared with 12% in both the ‘‘TB’’ and ‘‘no disease’’
groups. Seventy-five percent of participants in the ‘‘TB’’ group
had HIV-1 RNA level greater than or equal to 100,000 copies/mL
compared with 55% in the ‘‘other AIDS-defining disease’’ group
and 50% in the ‘‘no disease’’ group.
Overall, 329 of the 1571 participants (21%) experienced a
primary outcome event, including 287 (20%) in the ‘‘no disease’’
group, 31 (30%) in the ‘‘TB’’ group and 11 (20%) in the ‘‘other
AIDS-defining disease’’ group (Table 2). Figure 1 shows the
Kaplan-Meier curves for the proportion of participants without a
primary outcome event over time for each of the three disease
groups. There was a significant difference among the three groups
(p=0.042), reflecting a poorer outcome among participants in the
‘‘TB’’ group compared to the other two groups (Figure 1A).
In the overall study population, 56 participants (4%) died,
including 41 (3%) in the ‘‘no disease’’ group and 15 (15%) in the
‘‘TB’’ group (Table 2). Six deaths in the ‘‘TB group’’ were
considered HIV-related (two PCP and one of each miliary TB,
non-Hodgkin lymphoma, brain tuberculoma and chronic gastro-
enteritis), 7 were considered not related to HIV (three hepatitis
and one of each stroke, acute myocardial infarction, hydrocephaly
and stabbing) and two were not categorized (one cerebral
hemorrhage and one suicide). No deaths were reported among
the 56 participants in the ‘‘other AIDS-defining disease’’ group.
There was a highly significant difference among the three study
groups for the mortality outcome (p,0.001, Figure 1B), again
reflecting a poorer outcome among participants in the ‘‘TB’’
group. Forty percent of deaths in the ‘‘TB’’ group were recorded
as HIV related (PCP, ETB and lymphoma).
A total of 270 participants (17%) experienced virologic failure
during follow-up, including 239 (17%) in the ‘‘no disease’’ group,
21 (21%) in the ‘‘TB’’ group and 10 (18%) in the ‘‘other AIDS-
defining disease’’ group (Table 2). There was not a significant
difference among the three groups in distribution of time to
virologic failure (p=0.46, Figure 1C). The proportion of
participants experiencing AIDS-defining disease progression was
comparatively low: 46 participants (3%) in the overall study
population, including 40 (3%) in the ‘‘no disease’’ group, 5 (5%) in
the ‘‘TB’’ group and 1 (2%) in the ‘‘other AIDS-defining disease’’
group, with no significant difference among the groups (p=0.37,
Figure 1D).
Table 3 provides results from univariate and multivariate
analyses of the association between study group and risk of
experiencing a composite primary outcome and each component
of the primary outcome separately. In univariate analyses, the
‘‘TB’’ group was significantly associated with a higher risk of a
composite primary outcome. In the multivariate model, using the
group with no disease as reference, and adjusting for sex, age,
country, CD4+ cell count, viral load and randomized ART
assignment, an ongoing diagnosis of TB at randomization was
associated with an increased risk of the primary outcome (adjusted
hazard ratio [AHR] 1.38; 95%CI: 0.92–2.10) but this was not
statistically significant (p=0.11). There was no evidence that the
differences among disease groups varied by ART assignment.
When evaluating death as the primary outcome, the ‘‘TB’’ group
was significantly associated with a higher risk of death in the
univariate analysis. In the multivariate model which included sex,
age, country, CD4+ cell count, viral load, ART assignment and
the interaction term for sex and ART assignment, using the group
with no disease as reference, an ongoing diagnosis of TB at
randomization was associated with an increased risk of death
(AHR 3.41; 95%CI: 1.72–6.75) and this association was highly
significant (p,0.001). No significant association was found in
analyses of time to virologic failure or time to AIDS-defining
events.
ART Initiation and Opportunistic Infection
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Variable Categories
No disease
(n=1413)
TB
a (PTB+ETB)
(n=102)
Other AIDS-
defining
disease (n=56) Total (n=1571) p value
b
Sex Male 728 (51.5) 59 (57.8) 44 (78.6) 831 (52.9) ,0.001
Female 685 (48.5) 44 (42.2) 12 (21.4) 740 (47.1) –
Age (years) ,30 398 (28.2) 22 (21.6) 13 (23.2) 433 (27.6) 0.42
30–39 608 (43.0) 53 (52.0) 29 (51.8) 690 (43.9) –
40–49 314 (22.2) 19 (18.6) 12 (21.4) 345 (22.0) –
.=50 93 (6.6) 8 (7.8) 2 (3.6) 103 (6.5) –
Country Brazil 222 (15.7) 4 (3.9) 5 (8.9) 231 (14.7) ,0.001
Haiti 100 (7.1) 0 (0.0) 0 (0.0) 100 (6.4) –
India 198 (14.0) 57 (55.9) 0 (0.0) 255 (16.2) –
Malawi 205 (14.5) 10 (9.8) 6 (10.7) 221 (14.0) –
Peru 116 (8.2) 3 (2.9) 15 (26.8) 134 (8.5) –
South Africa 181 (12.8) 27 (26.5) 2 (3.6) 210 (13.4) –
Thailand 92 (6.5) 0 (0.0) 8 (14.3) 100 (6.4) –
United States 191 (13.5) 0 (0.0) 19 (33.9) 210 (13.4) –
Zimbabwe 108 (7.7) 1 (1.0) 1 (1.8) 110 (7.0) –
CD4 count (cells/mm
3) ,50 170 (12.0) 12 (11.8) 18 (32.1) 200 (12.7) ,0.001
50–99 190 (13.4) 27 (26.4) 12 (21.4) 229 (14.6) –
100–199 477 (33.8) 41 (40.2) 10 (17.9) 528 (33.6) –
200–299 576 (40.8) 22 (21.6) 16 (28.6) 614 (39.1) –
Viral load (c/mL) ,100,000 704 (49.8) 26 (25.5) 25 (44.6) 755 (48.0) ,0.001
$100,000 709 (50.2) 76 (74.5) 31 (55.4) 816 (52.0) –
Group allocation
c ZDV/3TC+ EFV 465 (32.9) 38 (37.2) 16 (28.6) 519 (33.0) 0.58
DDI+FTC+ ATV 480 (34.0) 28 (27.5) 18 (32.1) 526 (33.5) –
FTC/TDF+ EFV 468 (33.1) 36 (35.3) 22 (39.3) 526 (33.5) –
aTB=tuberculosis; PTB=pulmonary tuberculosis; ETB=extrapulmonary tuberculosis.
bp-values for categorical variables were obtained with the use of the chi-square test, while ANOVA test was used for continuous variables.
cZDV=zidovudine; 3TC=lamivudine; EFV=efavirenz; DDI=didanosine; TDF=tenofovir; FTC=emtricitabine.
doi:10.1371/journal.pone.0083643.t001
Table 2. Summary of events and follow-up (censoring) times by study group.
Endpoints Categories
No disease
(n=1413)
TB
a
(PTB+ETB) (n=102)
Other
AIDS-defining
disease (n=56)
Total
(n=1571)
Primary composite
outcome
b
Event – n(%) 287 (20.3) 31 (30.4) 11 (19.6) 329 (20.9)
Median time of follow-up for
outcomes (weeks)
176 178 168 –
Death Event – n(%) 41 (2.9) 15 (14.7) 0 (0.0) 56 (3.6)
Median time of follow-up for
outcomes (weeks)
184 186 183 –
Virologic failure Event – n(%) 239 (16.9) 21 (20.6) 10 (17.8) 270 (17.2)
Median time of follow-up for
outcomes (weeks)
177 179 169 –
New AIDS-defining
disease
Event – n(%) 40 (2.8) 5 (4.9) 1 (1.8) 46 (2.9)
Median time of follow-up for
outcomes (weeks)
184 184 176 –
aTB=tuberculosis; PTB=pulmonary tuberculosis; ETB=extrapulmonary tuberculosis.
bFirst of virologic failure, new AIDS-defining disease and death.
doi:10.1371/journal.pone.0083643.t002
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In univariate analyses, participants with ongoing TB at ART
initiation were more likely to experience a primary outcome
(virologic failure, AIDS-defining disease progression or death)
compared with participants with no AIDS-defining disease
(p=0.013). This finding appeared to be driven by a higher risk
of death (p,0.001). However, in multivariate analyses, although
the increased risk of a primary outcome in the TB group was not
statistically significant after controlling for confounding covariates
such as sex, ART regimen assignment, age, screening CD4+ cell
count and baseline viral load (p=0.11), the risk of death remained
significantly elevated (p,0.001). No death among participants in
the TB group was associated with immune reconstitution
inflammatory syndrome (IRIS). Of note, participants with TB
did not have an increased risk of virological failure so it is not likely
that they died as a result of ineffective ART. Among participants
with other active AIDS-defining diseases (most commonly
mucocutaneous herpes simplex or wasting syndrome), there was
not a significant difference in risk of a primary outcome, or
specifically of death, compared with participants with no active
AIDS-defining disease.
In 2010, Straetemans et al. published a meta-analysis of cohort
studies in which the authors evaluated outcomes among HIV-
infected patients with and without TB, and concluded that co-
infected patients had a higher risk of death compared to patients
without TB [11]. The same was not true for studies that included
patients receiving ART, in which no significant increase in risk was
found [11,21]. In 2011, Dronda et al. published the results of a
cohort study in Spain in which the authors evaluated various
outcomes in treatment naı ¨ve patients comparing those with a prior
diagnosis of TB versus other AIDS-defining illness (ADI) to those
without TB or ADI at ART initiation [22]. They concluded that a
previous diagnosis of TB or ADI did not compromise the
virological and immunological responses to treatment. However,
contrary to our findings, the authors found that a prior diagnosis of
an ADI other than TB, but not TB, was associated with an
increased risk of death when compared with patients who started
ART in the absence of a previous ADI. A difference in timing of
ART initiation may explain the difference in results (the median
time from TB diagnosis to ART initiation was 53 days in the
Spanish cohort and approximately 100 days in our study) as timing
of ART initiation in patients with TB has been shown to be an
important predictor of good response [12–14]. Havlir et al, showed
an improvement in survival in patients starting TB treatment
immediately (within 2 weeks) versus early (8–12 weeks), especially
among those with CD4+ cell counts below 50 cells/mm
3 [15].
However, TB immune reconstitution inflammatory syndrome
(IRIS) was more common with immediate ART. Despite the
increased risk of death in patients starting ARV with TB co-
infection, the risk could be higher without ARV treatment [15].
Such studies prompted the World Health Organization to update
Figure 1. Outcomes according to study group. Groups: ____ No OI; …. TB; –– Other OIs.
doi:10.1371/journal.pone.0083643.g001
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between 2 and 8 weeks of starting TB treatment [16]. Our study
lacked power to compare outcomes according to timing of ART
initiation relative to TB diagnosis, and the optimum time for ART
initiation is still open to debate [23,24].
Herein, we have presented a post hoc analysis of data from a
randomized clinical trial which was designed to evaluate the
efficacy of three different ART regimens. However, this compar-
ison of the three study groups according to the baseline occurrence
of an AIDS-defining disease is observational and hence is subject
to covariates that could confound the real association. This
analysis did account for a number of the important confounding
variables described in the literature and others that could be
related to the study design such as country and randomized
treatment assignment. The reason for increased risk of death in the
‘‘TB’’ group is unknown since our data show little mortality
attributable to TB or specific AIDS related complications. The
finding that non-tuberculosis AIDS diseases were not associated
with greater mortality is somewhat surprising and may reflect the
occurrence of less severe non-TB diseases among study partici-
pants. Although no restriction was made in the design of the
clinical trial on the inclusion of patients with AIDS-defining
diseases except that they should be on treatment and stable, it is
possible that sites may have chosen patients with HIV infection in
earlier stages to facilitate follow-up. The low number of AIDS-
defining diseases in our groups may have resulted in lower power
to detect differences among the groups and may explain the fact
that our results for the TB group did not reach statistical
significance in the multivariate analysis for the composite primary
outcome. However, we still observed that the TB group difference
is mostly driven by all-cause mortality, and these results were also
significant in the multivariate analysis.
Conclusion
Our results show that a diagnosis of active TB, but not AIDS-
defining disease, at ART initiation was associated with an
increased risk of morbidity and mortality in HIV-1 infected
patients. Of note, the increased risk for death persisted when
adjusted for important risk factors such as CD4+ cell count, viral
load and ART regimen. Our results reinforce the potential
importance of early HIV treatment in HIV-TB co-infection in
order to increase survival. Campaigns to increase HIV awareness
are essential to achieve earlier HIV testing prior to development of
TB that may, in turn, improve long-term survival among TB
patients. The data argue for earlier HIV diagnosis, but also the
need for more research to further understand the unique risks and
potential management strategies for those with TB at the time they
initiate ART.
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